{"paper_id":"168d8dcf-9f3c-4e6f-9bda-4c4223dafb17","body_text":"Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Center between 2018 and 2022 | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Center between 2018 and 2022 Olga Lucia Agudelo Rojas, María José Calle Salazar, Liliana María Tamayo Quijano, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4467272/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction: Atopic dermatitis (AD) is a chronic and recurrent inflammatory disease that begins in childhood and can persist into adulthood, with significant impact on quality of life. However, there is a lack of data on its characteristics and treatment in Colombia and Latin America. Objective: To describe the clinical and sociodemographic characteristics, quality of life, and treatment responses in patients with AD at a referral center in the city of Medellín, Colombia. Materials and Methods: A retrospective descriptive study was conducted analyzing demographic, clinical, and treatment response data, including biologic therapy, in patients with AD treated at the Comprehensive Clinical Program for Immune-Mediated Skin Diseases (CLIPSO) during the period 2018–2022 in Medellín, Colombia. Results: A total of 301 patients, including children and adults, with a mean age of 26.76 years were studied. 32.2% were under 18 years old. The average follow-up was 33.23 +/- 22.11 months. Psychiatric disorders were detected in 7.3% of patients and cardiovascular comorbidities in 10.6%. At baseline, moderate to severe disease severity was observed. A 50% reduction in pruritus was associated with adequate disease control by therapy. Additionally, patients treated with dupilumab experienced a 30% decrease in clinical evaluation scores during follow-up. Conclusions: Understanding the characteristics of a disease in both children and adults is crucial for comprehensive and personalized management. It is important to know data such as age of onset, symptoms, common lesion locations according to age, comorbidities, and treatment responses. This information is fundamental for selecting appropriate therapies, ensuring effective follow-up, and improving quality of life. dermatitis atopic prevalence treatment pruritus biological therapy Introduction Atopic dermatitis (AD) is a common chronic inflammatory disease, the prevalence of which varies significantly globally ( 1 ). It affects approximately 15–20% of children and 1–3% of adults, with a marked increase in recent decades ( 2 ). Studies show a geographical variation in prevalence, with values ranging from 0.9–22% in children aged 6–7 years in countries such as India and Ecuador, respectively, and from 0.2–24.6% in adolescents aged 13–14 years in countries such as China and Colombia ( 3 ). In adults, the prevalence varies between 2.1–4.9% in European multicenter studies ( 4 ). In Colombia, an increase in prevalence has been observed, with reports showing a rate of 659.1 per 100,000 population in 2019 ( 5 , 6 ). AD in adults is usually more severe and can affect sleep, social and work life, decreasing quality of life ( 7 ) The severity of the disease in adults is greater in persistent cases compared to those with adult onset ( 7 , 8 ). The pathogenesis involves genetic factors, skin barrier dysfunction and immune dysregulation ( 5 ). The clinical features may differ according to several factors, such as the age of the patient or the stage of disease development (acute or chronic). Xerosis and lichenification are more common during adolescence and adulthood, while lesions usually affecting the folds of the extremities, face and neck are more frequent in children ( 9 , 10 ). Treatment strategies have focused for years on disease severity, which is assessed with clinical scores. Topical interventions remain the main treatment option, but systemic therapy has also been recommended for patients with inadequate response to topical treatment ( 11 , 12 ). Phototherapy (UVB or narrowband UVA1) is mainly used for moderate disease. Severe atopic dermatitis often requires systemic therapy, the goals of which are effective treatment of acute flares and long-term disease control ( 13 ). Advances in knowledge about the pathogenesis of AD have allowed the promotion of new drugs, in addition to addressing the management of physical and psychological comorbidities to ensure comprehensive management, symptom control and disease remission, aiming at an increasingly personalized management ( 14 ). Information on the sociodemographic and clinical characteristics and response to treatment in patients with AD in Colombia and in Latin America in general is limited. Additionally, data on the response to treatments such as dupilumab in these patients are scarce in Latin America and there is no sociodemographic and epidemiological information associated with this therapy in the city of Medellín. Materials and methods An observational, longitudinal, retrospective cohort-type study was conducted with all patients with atopic dermatitis attending dermatology at IPS Helpharma, Medellin included in the CLIPSO-Clinical integral program of immune-mediated skin diseases, during the period 2018–2022. Patients from 2 years of age were included, all with clinical diagnosis issued by dermatology. The diagnosis of AD was defined considering the Hanifin and Rajka criteria. All patients were followed by specialists in allergology and dermatology who oversaw filling out the clinical histories, as well as performing disease severity scales and evaluation of response to treatment. Population and sample size We included patients with a clinical diagnosis of atopic dermatitis who were under management within the CLIPSO program, receiving different treatment therapies including the use of dupilumab. We collected demographic, clinical and treatment data. All data were obtained directly from medical records, the inclusion criteria were as follows: registration of patients with a diagnosis of atopic dermatitis, patients receiving systemic therapies or biologics such as dupilumab. Patients with loss of more than 10% of the data in the medical records were excluded. The selection of clinical features and phenotypes was made based on what was described in the literature. Patients were classified into three groups according to the type of treatment received, the first group received only biologic therapy, the second group received topical therapy and, systemic therapy or topical therapy and phototherapy and a third group received biologic therapy and topical therapy. Variables Demographic and clinical variables and disease severity scales to evaluate response to treatment were collected from the clinical history of each patient. Disease severity scales measurements were considered including EASI, POEM, DLQI values both at the beginning of the defined evaluation period as well as at the end, which were considered dependent variables. In addition, the presence of pruritus, its intensity and control after the establishment of the different treatments were evaluated. Statistical analysis A descriptive analysis was performed estimating percentages for categorical variables, means and standard deviation for symmetrical quantitative variables and medians with interquartile ranges for asymmetrical variables. Qualitative variables are presented as absolute frequencies and percentages. Qualitative variables were compared using the chi-square test or Fisher's exact test, as appropriate. Quantitative variables were compared with the Mann Whitney U test or Kruskall-Wallis Anova. A p value of less than 0.05 was considered statistically significant. All analyses were performed in SPSS version 25 software. Results The study included 301 patients seen in the period from May 2018 to December 2022, whose sociodemographic characteristics are presented in Table 1. The mean follow-up time for this group of patients was 33.23 +/- 22.11 months. The average age of the patients evaluated was 26.76 years (IQR of (19.95). 32.2% of the patients were younger than 18 years old. 62.8% of the patients were women. Table 2 shows family and pathologic history, clinical manifestations, and the most frequently affected locations according to age. In 65.1% of the patients evaluated, symptoms occurred before 2 years of age, while in 32.4% of the population, symptoms began in adolescence or adulthood. Of the stigmata of atopy, 83.7% of patients had xerosis, 25.2% had facial pallor, 38.9% had lichenification. The tendency to develop skin infections was present in 14.7% of the evaluated population. Table 3. shows the frequencies of comorbidities associated with AD. Among the atopic comorbidities in the patients evaluated, allergic rhinitis 39.5% was the most frequently observed, followed by asthma 14.9%, while food allergy was present in only 1.9%. Regarding psychiatric disorders and disorders associated with increased cardiovascular risk. Psychiatric disorders were observed in 7.3% of the total population evaluated, depression was the most frequent psychiatric disorder in 22.7%, followed by anxiety and attention deficit was 18.2%. Comorbidities associated with cardiovascular risk were present in 10.6% of the population, with obesity (28.1%), arterial hypertension (18.8%) and dyslipidemia (15.6%) being the most frequently found. Type 2 diabetes mellitus was reported in association with other comorbidities in the same group, finding that the coexistence of type 2 diabetes and dyslipidemia was the most frequent, with 9.4% in the total population. Table 4 shows the treatments used in the study population. All patients were receiving some type of therapy or a combination of these. Of the 301 patients evaluated, 91.0% were receiving topical therapy. With respect to systemic management, methotrexate was used in 34.9%, cyclosporine in 21.2%, mycophenolate mofetil 1.5%, azathioprine 5.5% and biological therapy 44.5% of the patients. The use of phototherapy was evaluated, 25.17% had received this as sole therapy or combined with other systemic and biologic therapies. Atopic dermatitis was moderate to severe at the beginning of follow-up in those patients who were receiving or had received systemic treatment (oral corticosteroids, azathioprine, methotrexate, cyclosporine) and/or phototherapy. About the disease severity scales the EASI, POEM and DLQI scores were considered, and the presence or absence of pruritus at the beginning and end of follow-up was evaluated as an indicator of improvement and control of the disease, the data are presented in Table N.5 and Table N.6. The mean EASI at study entry in the total population evaluated was 11.24 and a mean at the end of the follow-up time of 6.41. With the DLQI and POEM scales we have admission means of 10.54 which corresponded to a significant impact on quality of life and 15.14 respectively. The means at the end of follow-up were 6.20 for DLQI and 8.75 for POEM. Regarding the pruritus evaluation scale Table 6 . Up to 56.1% of the population evaluated experienced daily pruritus beginning of the follow-up and the end of the follow-up period, only 17.7% of the entire population still reported pruritus. A reduction of this symptom by more than 50% is indicative of effective disease control with the prescribed therapies. Specifically, among patients receiving dupilumab therapy, there was an average reduction in disease severity scales of over 30% from the beginning to the end of follow-up. Discussion Atopic dermatitis is a disease that has been increasing in recent decades. It usually presents in childhood, however the prevalence of the disease in adolescents and adults has been increasing ( 8 , 15 ). Data on the prevalence of AD in these populations is scarce, with very few studies describing the age of onset, behavior, and frequency of the disease at these ages ( 8 ). Our study included children and adults with a diagnosis of atopic dermatitis; of the total population evaluated, only 32.2% were younger than 18 years of age. In 65.1% of the patients evaluated, the age of symptom onset was before 2 years of age. Comparing data from the literature and our data, we can highlight that the frequency of the disease in adults is significant, as well as the relevance of the age of onset in this population and the frequency of persistence of the disease that started in childhood ( 16 ). Recent studies suggest that there is considerable heterogeneity in the age of onset of AD, highlighting the fact that 1 in 4 adults with AD report that their disease began in adulthood ( 17 ). Our study had a predominance of adult patients, in which the most frequent location of the lesions were the flexural folds and extensor surfaces, in contrast to populations younger than 18 years, in which the most frequent location included both extensor surfaces and the face. In the literature we found that AD in adulthood is associated with higher rates of plantar dermatitis, lower predominance of lesions in flexural areas and lower rates of other characteristic signs ( 17 , 18 ). This makes diagnosis more difficult at this age, increasing the difficulty in distinguishing AD from other entities such as allergic contact dermatitis and cutaneous T-cell lymphoma ( 18 ). The development of the disease or its persistence associated with the severity of AD in adults jeopardizes productivity and the rate of labor insertion ( 19 ). The severity and complications of AD may be associated with the tendency to develop skin infections, which in our study was present in 14.7% of the population evaluated. These infections usually begin in a focal area of the skin but can spread rapidly and cover extensive areas of the body surface. It is important to be able to differentiate severe exacerbation from AD which may have more generalized cutaneous signs and symptoms such as erythema, swelling, oozing and tenderness, all of which can also be signs of skin infections ( 16 ). Given the impact of AD on patients' quality of life. We found that in the patients evaluated there was a significant decrease in the DLQI value at the end of follow-up. Considering that the good control of the disease is not only influenced by the adequate selection of therapies, but also by the multidisciplinary management of these patients and the capacity to respond to any complication. The evaluation of underlying psychiatric disorders helps to improve the quality of life of patients, achieving greater adherence to therapies and better response rates to the established treatments. There is emerging evidence suggesting that AD is associated with depression and anxiety ( 20 ). Some 30–60% of patients with dermatologic disease have some type of mental health problem ( 18 ). In a case-control study exploring routinely collected data from the UK Clinical Practice Research Datalink, a significantly increased risk of depression as well as anxiety incidence in patients with AD was demonstrated ( 18 , 21 ). Our study reveals a prevalence of psychiatric disorders in up to 7.3% of the total population under evaluation, a figure notably lower compared to other studies where frequencies of up to 18.8% have been documented. The lower incidence of psychiatric disorders observed in our study may be attributed to several factors. Firstly, our patient follow-up program lacks the involvement of medical specialists in psychiatry. Additionally, when referrals to health insurance companies are made, the availability of specialists in this field is limited, resulting in lengthy waiting times for appointments. Furthermore, the absence of standardized employment of psychiatric evaluation scales during assessments hampers the detection of such pathologies ( 22 ). This agrees with reports in the literature, which highlight that obesity is one of the comorbidities defined as a risk factor for AD and has also been associated with more severe disease. However, the specific mechanisms that explain the connection between obesity and AD are not yet fully recognized ( 23 , 24 ). Obesity is known to be a metabolic disorder that often manifests early in life and is associated with reduced bacterial diversity in the gastrointestinal tract. Several lines of evidence suggest that obesity increases the severity of allergic diseases. Obese patients with immune diseases such as atopy and asthma have more severe disease compared to lean individuals ( 24 ). The identification of these risk factors and the intervention to correct them is of great importance for the adequate control of symptoms in patients with atopic dermatitis. The results of our study coincide with the literature, showing that topical therapy including emollients, topical steroids and calcineurin inhibitors are the most frequently used combinations of therapy with a percentage of 91% in the evaluated population. Systemic therapies are the first option in severe AD, the selection of these therapies is made based on the severity of the disease and according to previous therapies received. The use of biologic therapy is indicated in patients with severe clinical and quality of life impairment. Among the biologic products, dupilumab is authorized in other countries for children from 6 months of age and in Colombia from 6 years of age ( 25 ). Oral JAK inhibitors, such as baricitinib, abrocitinib and upadacitinib, have been approved in adolescents when other drugs, including biologics, have failed, or are contraindicated ( 13 ). Data on the use of these biologic therapies or others such as crisaborole were not included in the study, as they were approved after the recruitment dates of the study patients. It is crucial to understand the characteristics of a disease in children and adults for a complete and personalized management. It is important to know data such as age of onset, symptoms, location of common lesions according to age, comorbidities, and responses to treatments. This information is essential for choosing appropriate therapies, ensuring effective follow-up, and improving quality of life. The participants of this study constitute a representative cohort of patients with atopic dermatitis followed in a health institution specialized in the management and control of immune-mediated diseases. The availability and use of biologic drugs has expanded treatment options for patients with moderate to severe AD, particularly for those who have not achieved satisfactory results with conventional therapies or who have contraindications to systemic immunosuppressive agents. These drugs provide a more targeted and personalized approach, reducing symptoms, improving quality of life and preventing long-term complications associated with uncontrolled disease as we see in the results. Limitations Although important and complete information is shown for a significant number of patients with AD, we consider that the follow-up time was short, which limits the evaluation of the effect of the therapy or the use of other therapies. Most of the patients belong to the contributory health care system; we do not know information on the characteristics and behavior of the population in other socioeconomic spheres, where probably the lack of access to this type of programs may show a greater severity of symptoms and a limitation in the use of therapies for the control of the disease. Since the clinical histories are not pre-tabulated, there were variables with few data, other data do not appear since the study was retrospective. The prevalence of psychiatric disorders related to the disease was low; we suggest the implementation of screening scales for these pathologies to assess their impact on the severity of the disease. It is important given the frequency of these reported in the literature that they be included in the follow up evaluation by psychiatry. Abbreviations AD Atopic dermatitis CLIPSO Clinical Program for Immune-Mediated Skin Diseases UVB Ultraviolet B UVA1 Ultraviolet A1 EASI Eczema Area and Severity Index POEM Patient Oriented Eczema Measure DLQI Dermatology Life Quality Index Declarations Ethical approval: This research article was reviewed and approved by the Research and Innovation Committee of the Faculty of Medicine, Universidad CES, No. Act No. 289 of August 17, 2022, and was conducted following the Declaration of Helsinki and recommendations of the Council for International Organizations of Medical Sciences. Acknowledgements: Don’t apply Consent to publish statement: Patient consent was not required because this study was performed retrospectively. Conflict of Interest Statement: The authors declare that they have no competing interests to disclose. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Author Contributions: All authors contributed equally to this work. Data Availability Statement: The data sets used during the present study are available from the corresponding author upon reasonable request. References Sonja Ständer 1. Atopic Dermatitis. N Engl J Med. 2021;25(384(12)):1136–43. Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment. ISRN Allergy. 2014;2014:1–7. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(Suppl. 1):8–16. Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605. Londoño AM, Castro-Ayarza JR, Kronfly A, Buitrago DC, Samacá DF. Epidemiología y uso de recursos de salud en dermatitis atópica en Colombia: análisis retrospectivo de datos del Registro Nacional de Salud de 2015 a 2020. Biomédica. 2023;43(1):107–20. Cuervo MM, Sanclemente G, Barrera LM. Caracterización clínica, sociodemográfica y determinación del impacto en la calidad de vida de pacientes con dermatitis atópica de la ciudad de Medellín y su área metropolitana. Biomédica. 2021;41(4):676–91. Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448–74. Ramírez-Marín HA, Silverberg JI. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022;39(3):345–53. Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324–38. Radi G, Campanti A, Diotallevi F, Martina E, Marani A, Offidani A. A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside. Biomedicines. 2022;10(11):2700. Gooderham M, Boguniewicz M, Sher L, Weisman J, Bansal A, Staudinger HW, et al. Dupilumab in children aged ≥ 6 to < 12 years significantly improves severe atopic dermatitis: Results from phase 3 trial (LIBERTY AD PEDS). Australasian Journal of Dermatology. 2021;62(SUPPL 1). Caffarelli C, Giannetti A, Giannì G, Ricci G. Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. Front Med (Lausanne). 2023;10. Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to‐severe atopic dermatitis: A network meta‐analysis. Dermatol Ther. 2022;35(9). Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51. Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e7. Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Annals of Allergy, Asthma & Immunology. 2021;126(1):3–12. Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index—A Practical Guide. Dermatitis. 2022;33(3):187–92. Barbieri JS, Chiesa Fuxench ZC, Shin DB, Takeshita J. Frequency and influence of “not relevant” responses on the Dermatology Life Quality Index among adults with atopic dermatitis. Quality of Life Research. 2021;30(6):1705–13. Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–9. Baurecht H, Welker C, Baumeister S -E., Weidnger S, Meisinger C, Leitzmann MF, et al. Relationship between atopic dermatitis, depression and anxiety: a two‐sample Mendelian randomization study. British Journal of Dermatology. 2021;185(4):781–6. Tohid H, Shenefelt PD, Burney WA, Aqeel N. Psychodermatology: An Association of Primary Psychiatric Disorders With Skin. Rev Colomb Psiquiatr. 2019;48(1):50–7. Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol [Internet]. 2018;79(3):448–456.e30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962218304675 Zhang S, Zhang B, Liu Y, Li L. Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis. Lipids Health Dis [Internet]. 2024;23(1):26. Available from: https://lipidworld.biomedcentral.com/articles/ 10.1186/s12944-024-02009-z McAleer JP. Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists. Frontiers in Allergy [Internet]. 2023;4. Available from: https://www.frontiersin.org/articles/ 10.3389/falgy.2023.1167800/full Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults. Dtsch Arztebl Int. 2023; doi: 10.3238/arztebl.m2023.001 . Tables Table N.1 Demographic data of patients with Atopic Dermatitis and subpopulation of patients with AD receiving biologic therapy. Table N°1. Demographic data of patients with Atopic Dermatitis Patients with Atopic Dermatitis Total (n= 301) Patients with AD who received biological therapy Demographic Characteristics n (%) Total (n= 134) Mean age (IQR) 26,76 (19,95) 27.99(13,67) Gender, n (%) Female 189(62,8) 86(64,2) Male 112(37,2) 48(35,8) Marital status Single 236(78,4) 101(75,4) Married 35(11,6) 15(11,2) Unmarried 23(7,6) 15(11,2) Divorced 5(1,7) 3(2,2) widowed 2(0,7) 0(0) Affiliation Contributory 293(97,3) 129(96,3) Special 8(2,7) 5(3,7) Geographic region n (%) Antioquia 288(95,7) 128(95,5) Bogotá DC 1(0,3) 1(0,7) Cauca 1(0,3) 0(0) Valle del Cauca 11(3,7) 5(3,7) Zone Urban 298(99) 131(97,8) Rural 3(1) 3(2,2) Schooling Primary 55(18,3) 14(10,9) Secondary 118(39,2) 51(39,5) Professional 64(21,3) 42(32,6) Postgraduate 3(1,0) 5(3,9) No studies 16(5,3) 17(13,2) Technical/technological 37(12,3) 0(0) Socioeconomic stratum Low 62(20,6) 21(15,7) Medium 213(70,7) 96(71,6) High 26(8,7) 17(12,6) Table N. 2 Clinical characteristics of patients with Atopic Dermatitis TableN°2 Clinical characteristics of patients with Atopic Dermatitis n (%) Early onset in childhood (<2 years) 196(65,1) Chronic Recurrent Symptoms 289(96,0) Distribution of skin lesions Total=294 Facial 7(2,3) Flexural folds 68(22,6) Extensor surfaces 31(10,3) Facial and flexural folds 32(10,6) Facial and extensor surfaces 17(5,6) Flexural folds and extensor surfaces 69(22,9) Facial, flexural folds, extensor surfaces 70(23,3) Distribution of lesions by age range 2-12 years 13-17 years > 18 years Age ranges n (%) Total =301 46(15,28) 51(16,94) 204(67,77) Facial 0(0) 1(1,9) 6(2,94) Flexural folds 3(6,97) 10(19,60) 55(26,96) Extensor surfaces 6(13,04) 1(1,9) 24(11,76) Facial and flexural folds 0(0) 3(5,88) 29(14,21) Facial and extensor surfaces 5(10,86) 21(41,1) 12(5,88) Flexural folds and extensor surfaces 6(13,04) 14(27,45) 72(35,29) Atopic stigmata Xerosis 253(83,7) Facial pallor 76(25,2) Dermographism 3(1,0) Ichthyosis 2(7.0) Palmar hyperlinearity 19(6,3) Pityriasis Alba 20(6,6) Pilar keratosis 20(6,6) Perifollicular accentuation 23(7,6) Periocular darkening 48(15,9) Lichenification 117(38,9) Tendency to cutaneous infections 44(14,6) Family History (n=301) n (%) Asthma 26(8,6) Rhinitis 39(13,0) Atopic dermatitis 44(14,6) Asthma and rhinitis 61(20,3) Asthma and atopic dermatitis 15(5,0) Asthma, rhinitis, dermatitis 39(13,0) Table N.3: Associated Comorbidities in Patients with Atopic Dermatitis Atopic Comorbidities (n=215) n (%) Asthma 32(14.9) Rhinitis 85(39.5) Food allergy 4(1.9) Asthma/rhinitis 76(35.3) Asthma/food allergy 5(2.3) Rhinitis/food allergy 4(1.9) Asthma/rhinitis/dermatitis 9(4.2) Psychiatric Comorbidities (n=22) n (%) Anxiety 4(18.2) Depression 5(22.7) Schizophrenia 1(4.5) Bipolar affective disorder 1(4.5) Attention deficit 4(18.2) Anxiety/depression 3(13.6) Anxiety/depression/suicidal behavior 1(4.5) Anxiety/depression/attention deficit 3(13.6) Other Comorbidities (n=32) n (%) Microcytic anemia 1(3.1) Dyslipidemia 5(15.6) Type 2 Diabetes Mellitus 1(3.1) Obesity 9(28.1) Arterial hypertension 6(18.8) Type 2 DM/dyslipidemia 3(9.4) Type 2 DM/arterial hypertension/obesity 3(9.4) Arterial hypertension/dyslipidemia 1(3.1) Arterial hypertension/coronary artery disease 1(3.1) Arterial hypertension/chronic kidney disease 1(3.1) Arterial hypertension/type 2 DM/dyslipidemia/coronary artery disease 1(3.1) Table N.4 Combination of therapies used in the management of patients with atopic dermatitis. Table N.4 Combination of therapies used in the management of patients with atopic dermatitis Treatment (n=294) n (%) Topical therapy 274(91.0) Emollients 10(3.3) Corticosteroids 26(9.4) Tacrolimus 10(3.3) Emollients/Corticosteroids 42(15.3) Emollients/Tacrolimus 5(1,8) Corticosteroids/Tacrolimus 35(12.7) Emollients/Corticosteroids/Tacrolimus 145(52.9 Non-biologic systemic therapy 197(65.4) Azathioprine 1(0,3) Methotrexate 45(22,8) Cyclosporine 30(10,0) Corticosteroids 12(6,1) Mycophenolate mofetil 2(1,0) Combinations 40(20,2) Phototherapy 74(25,17) Systematic Biological Therapy Dupilumab 134(44.5) Baricitinid 2(0,66) Table No. 5: Clinical measurements at the beginning and end of follow-up in patients with AD, variations according to treatment Treatment (n=294) POEM score Initial POEM score final EASI score initial EASI score final DLQI score initial DLQI score final Topical therapy 15,96(8,65) 8,73(7,23) 11,44(12,33) 6,39(9,33) 10,5(8,46) 6,27(6,7) Non-biological systemic therapy 14,17(8,25) 10,16(7,39) 11,57(10,73) 6,92(7,08) 11,26(8,09) 7,87(7,27) Methotrexate 14,57(8,54) 10,86(6,68) 13,41(9,72) 7,61(7,1) 11,30(7,60) 6,94(6,86) Cyclosporine 14,92(8,55) 8,96(7,31) 11,22(11,79) 6,31(9,15) 11,37(8,54) 6,14(6,4) Phototherapy 15,11(8,64) 8,98 (7,31) 11,23(12,25) 6,21(9,49) 10,61(8,52) 6,26(6,68) Biological therapy 14,86(8,86) 7,97(7,38) 12,30(12,61) 6,35(8,82) 11,32(9,06) 5,84(6,66) Data are mean (+/-SD) Table No. 6: Evaluation of pruritus at the beginning and end of follow-up Pruritus (Follow-up) Beginning (n=285) End(n=259) n (%) n (%) No day 28(9,8) 84(32,43) 1-2 Days 36(12,6) 84(32,43) 3-4 Days 31(10,9) 38(14,67) 5-6 Days 21(7,0) 6(2,31) Every day 169(56,1) 46(17,76) Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-4467272\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":true,\"archivedVersions\":[],\"articleType\":\"Research Article\",\"associatedPublications\":[],\"authors\":[{\"id\":313878252,\"identity\":\"8b7d12b6-c892-4478-9f69-c4585fb62f4d\",\"order_by\":0,\"name\":\"Olga Lucia Agudelo Rojas\",\"email\":\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAvUlEQVRIiWNgGAWjYDACdiBO/GcDJBkbDxCnhRmIH7ClgbQ0EK+F8QHbYTCbOC38zMzPPiTwnLdb234YaEuNTTRBLZLNbMYzEiRuJ287kwjUciwtt4GQFoPDDMYMCQa3k80OALUwNhwmRgv7Z4aEhHPJZucfEq2FB2jLgQN2ZjeItUWymaeYIbEhOcHsBtCWBGL8ws/evpnxZ4Odvdn59IcPPtTYENYCA4lglQnEKgcBe1IUj4JRMApGwQgDALraRADDN8fYAAAAAElFTkSuQmCC\",\"orcid\":\"\",\"institution\":\"Universidad CES\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Olga\",\"middleName\":\"Lucia Agudelo\",\"lastName\":\"Rojas\",\"suffix\":\"\"},{\"id\":313878253,\"identity\":\"06c2537f-6a5f-4a4e-841d-243c13cd16ad\",\"order_by\":1,\"name\":\"María José Calle Salazar\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Universidad CES\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"María\",\"middleName\":\"José Calle\",\"lastName\":\"Salazar\",\"suffix\":\"\"},{\"id\":313878254,\"identity\":\"0cbc0b70-ef31-49e2-939c-9774aeb5ae57\",\"order_by\":2,\"name\":\"Liliana María Tamayo Quijano\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Research Group in Pharmacoepidemiology and Health Risk Management\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Liliana\",\"middleName\":\"María Tamayo\",\"lastName\":\"Quijano\",\"suffix\":\"\"},{\"id\":313878255,\"identity\":\"a6665a81-6954-46d7-a53b-ac7875528322\",\"order_by\":3,\"name\":\"Margarita Velásquez-Lopera\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Research Group in Pharmacoepidemiology and Health Risk Management\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Margarita\",\"middleName\":\"\",\"lastName\":\"Velásquez-Lopera\",\"suffix\":\"\"},{\"id\":313878256,\"identity\":\"ed52a391-02fb-4365-853d-9fd3f4e27517\",\"order_by\":4,\"name\":\"Elsa María Vásquez Trespalacios\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Universidad CES\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Elsa\",\"middleName\":\"María Vásquez\",\"lastName\":\"Trespalacios\",\"suffix\":\"\"},{\"id\":313878257,\"identity\":\"3df64a93-9f4b-4e38-9ebc-0afb970111dd\",\"order_by\":5,\"name\":\"Juliana Madrigal-Cadavid\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Research Group in Pharmacoepidemiology and Health Risk Management\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Juliana\",\"middleName\":\"\",\"lastName\":\"Madrigal-Cadavid\",\"suffix\":\"\"},{\"id\":313878258,\"identity\":\"f8526bf3-31b1-424a-b30d-278def4588de\",\"order_by\":6,\"name\":\"Angela María Londoño García\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Universidad CES\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Angela\",\"middleName\":\"María Londoño\",\"lastName\":\"García\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2024-05-23 13:44:18\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-4467272/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-4467272/v1\",\"draftVersion\":[],\"editorialEvents\":[],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":60304822,\"identity\":\"41bffc90-6517-4eb2-ac9d-11f5cc3e26ab\",\"added_by\":\"auto\",\"created_at\":\"2024-07-15 11:37:22\",\"extension\":\"pdf\",\"order_by\":0,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":1155460,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"manuscript.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4467272/v1/890527b9-38d6-46e6-b0de-ac73dae39ccf.pdf\"}],\"financialInterests\":\"No competing interests reported.\",\"formattedTitle\":\"Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Center between 2018 and 2022\",\"fulltext\":[{\"header\":\"Introduction\",\"content\":\"\\u003cp\\u003eAtopic dermatitis (AD) is a common chronic inflammatory disease, the prevalence of which varies significantly globally (\\u003cspan citationid=\\\"CR1\\\" class=\\\"CitationRef\\\"\\u003e1\\u003c/span\\u003e). It affects approximately 15\\u0026ndash;20% of children and 1\\u0026ndash;3% of adults, with a marked increase in recent decades (\\u003cspan citationid=\\\"CR2\\\" class=\\\"CitationRef\\\"\\u003e2\\u003c/span\\u003e). Studies show a geographical variation in prevalence, with values ranging from 0.9\\u0026ndash;22% in children aged 6\\u0026ndash;7 years in countries such as India and Ecuador, respectively, and from 0.2\\u0026ndash;24.6% in adolescents aged 13\\u0026ndash;14 years in countries such as China and Colombia (\\u003cspan citationid=\\\"CR3\\\" class=\\\"CitationRef\\\"\\u003e3\\u003c/span\\u003e). In adults, the prevalence varies between 2.1\\u0026ndash;4.9% in European multicenter studies (\\u003cspan citationid=\\\"CR4\\\" class=\\\"CitationRef\\\"\\u003e4\\u003c/span\\u003e). In Colombia, an increase in prevalence has been observed, with reports showing a rate of 659.1 per 100,000 population in 2019 (\\u003cspan citationid=\\\"CR5\\\" class=\\\"CitationRef\\\"\\u003e5\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR6\\\" class=\\\"CitationRef\\\"\\u003e6\\u003c/span\\u003e). AD in adults is usually more severe and can affect sleep, social and work life, decreasing quality of life (\\u003cspan citationid=\\\"CR7\\\" class=\\\"CitationRef\\\"\\u003e7\\u003c/span\\u003e) The severity of the disease in adults is greater in persistent cases compared to those with adult onset (\\u003cspan citationid=\\\"CR7\\\" class=\\\"CitationRef\\\"\\u003e7\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR8\\\" class=\\\"CitationRef\\\"\\u003e8\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eThe pathogenesis involves genetic factors, skin barrier dysfunction and immune dysregulation (\\u003cspan citationid=\\\"CR5\\\" class=\\\"CitationRef\\\"\\u003e5\\u003c/span\\u003e). The clinical features may differ according to several factors, such as the age of the patient or the stage of disease development (acute or chronic). Xerosis and lichenification are more common during adolescence and adulthood, while lesions usually affecting the folds of the extremities, face and neck are more frequent in children (\\u003cspan citationid=\\\"CR9\\\" class=\\\"CitationRef\\\"\\u003e9\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR10\\\" class=\\\"CitationRef\\\"\\u003e10\\u003c/span\\u003e). Treatment strategies have focused for years on disease severity, which is assessed with clinical scores. Topical interventions remain the main treatment option, but systemic therapy has also been recommended for patients with inadequate response to topical treatment (\\u003cspan citationid=\\\"CR11\\\" class=\\\"CitationRef\\\"\\u003e11\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR12\\\" class=\\\"CitationRef\\\"\\u003e12\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003ePhototherapy (UVB or narrowband UVA1) is mainly used for moderate disease. Severe atopic dermatitis often requires systemic therapy, the goals of which are effective treatment of acute flares and long-term disease control (\\u003cspan citationid=\\\"CR13\\\" class=\\\"CitationRef\\\"\\u003e13\\u003c/span\\u003e). Advances in knowledge about the pathogenesis of AD have allowed the promotion of new drugs, in addition to addressing the management of physical and psychological comorbidities to ensure comprehensive management, symptom control and disease remission, aiming at an increasingly personalized management (\\u003cspan citationid=\\\"CR14\\\" class=\\\"CitationRef\\\"\\u003e14\\u003c/span\\u003e). Information on the sociodemographic and clinical characteristics and response to treatment in patients with AD in Colombia and in Latin America in general is limited. Additionally, data on the response to treatments such as dupilumab in these patients are scarce in Latin America and there is no sociodemographic and epidemiological information associated with this therapy in the city of Medell\\u0026iacute;n.\\u003c/p\\u003e\"},{\"header\":\"Materials and methods\",\"content\":\"\\u003cp\\u003eAn observational, longitudinal, retrospective cohort-type study was conducted with all patients with atopic dermatitis attending dermatology at IPS Helpharma, Medellin included in the CLIPSO-Clinical integral program of immune-mediated skin diseases, during the period 2018\\u0026ndash;2022. Patients from 2 years of age were included, all with clinical diagnosis issued by dermatology. The diagnosis of AD was defined considering the Hanifin and Rajka criteria. All patients were followed by specialists in allergology and dermatology who oversaw filling out the clinical histories, as well as performing disease severity scales and evaluation of response to treatment.\\u003c/p\\u003e \\u003cdiv id=\\\"Sec3\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003ePopulation and sample size\\u003c/h2\\u003e \\u003cp\\u003eWe included patients with a clinical diagnosis of atopic dermatitis who were under management within the CLIPSO program, receiving different treatment therapies including the use of dupilumab. We collected demographic, clinical and treatment data. All data were obtained directly from medical records, the inclusion criteria were as follows: registration of patients with a diagnosis of atopic dermatitis, patients receiving systemic therapies or biologics such as dupilumab. Patients with loss of more than 10% of the data in the medical records were excluded. The selection of clinical features and phenotypes was made based on what was described in the literature. Patients were classified into three groups according to the type of treatment received, the first group received only biologic therapy, the second group received topical therapy and, systemic therapy or topical therapy and phototherapy and a third group received biologic therapy and topical therapy.\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec4\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003eVariables\\u003c/h2\\u003e \\u003cp\\u003eDemographic and clinical variables and disease severity scales to evaluate response to treatment were collected from the clinical history of each patient. Disease severity scales measurements were considered including EASI, POEM, DLQI values both at the beginning of the defined evaluation period as well as at the end, which were considered dependent variables. In addition, the presence of pruritus, its intensity and control after the establishment of the different treatments were evaluated.\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec5\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003eStatistical analysis\\u003c/h2\\u003e \\u003cp\\u003eA descriptive analysis was performed estimating percentages for categorical variables, means and standard deviation for symmetrical quantitative variables and medians with interquartile ranges for asymmetrical variables. Qualitative variables are presented as absolute frequencies and percentages. Qualitative variables were compared using the chi-square test or Fisher's exact test, as appropriate. Quantitative variables were compared with the Mann Whitney U test or Kruskall-Wallis Anova. A p value of less than 0.05 was considered statistically significant. All analyses were performed in SPSS version 25 software.\\u003c/p\\u003e \\u003c/div\\u003e\"},{\"header\":\"Results\",\"content\":\"\\u003cp\\u003eThe study included 301 patients seen in the period from May 2018 to December 2022, whose sociodemographic characteristics are presented in Table\\u0026nbsp;1. The mean follow-up time for this group of patients was 33.23 +/- 22.11 months. The average age of the patients evaluated was 26.76 years (IQR of (19.95). 32.2% of the patients were younger than 18 years old. 62.8% of the patients were women. \\u003cb\\u003eTable\\u0026nbsp;2\\u003c/b\\u003e shows family and pathologic history, clinical manifestations, and the most frequently affected locations according to age. In 65.1% of the patients evaluated, symptoms occurred before 2 years of age, while in 32.4% of the population, symptoms began in adolescence or adulthood. Of the stigmata of atopy, 83.7% of patients had xerosis, 25.2% had facial pallor, 38.9% had lichenification. The tendency to develop skin infections was present in 14.7% of the evaluated population.\\u003c/p\\u003e \\u003cp\\u003e \\u003cb\\u003eTable\\u0026nbsp;3.\\u003c/b\\u003e shows the frequencies of comorbidities associated with AD. Among the atopic comorbidities in the patients evaluated, allergic rhinitis 39.5% was the most frequently observed, followed by asthma 14.9%, while food allergy was present in only 1.9%. Regarding psychiatric disorders and disorders associated with increased cardiovascular risk. Psychiatric disorders were observed in 7.3% of the total population evaluated, depression was the most frequent psychiatric disorder in 22.7%, followed by anxiety and attention deficit was 18.2%. Comorbidities associated with cardiovascular risk were present in 10.6% of the population, with obesity (28.1%), arterial hypertension (18.8%) and dyslipidemia (15.6%) being the most frequently found. Type 2 diabetes mellitus was reported in association with other comorbidities in the same group, finding that the coexistence of type 2 diabetes and dyslipidemia was the most frequent, with 9.4% in the total population.\\u003c/p\\u003e \\u003cp\\u003e \\u003cb\\u003eTable\\u0026nbsp;4\\u003c/b\\u003e shows the treatments used in the study population. All patients were receiving some type of therapy or a combination of these. Of the 301 patients evaluated, 91.0% were receiving topical therapy. With respect to systemic management, methotrexate was used in 34.9%, cyclosporine in 21.2%, mycophenolate mofetil 1.5%, azathioprine 5.5% and biological therapy 44.5% of the patients. The use of phototherapy was evaluated, 25.17% had received this as sole therapy or combined with other systemic and biologic therapies.\\u003c/p\\u003e \\u003cp\\u003eAtopic dermatitis was moderate to severe at the beginning of follow-up in those patients who were receiving or had received systemic treatment (oral corticosteroids, azathioprine, methotrexate, cyclosporine) and/or phototherapy. About the disease severity scales the EASI, POEM and DLQI scores were considered, and the presence or absence of pruritus at the beginning and end of follow-up was evaluated as an indicator of improvement and control of the disease, the data are presented in \\u003cb\\u003eTable N.5 and Table N.6.\\u003c/b\\u003e\\u003c/p\\u003e \\u003cp\\u003eThe mean EASI at study entry in the total population evaluated was 11.24 and a mean at the end of the follow-up time of 6.41. With the DLQI and POEM scales we have admission means of 10.54 which corresponded to a significant impact on quality of life and 15.14 respectively. The means at the end of follow-up were 6.20 for DLQI and 8.75 for POEM. Regarding the pruritus evaluation scale \\u003cb\\u003eTable\\u0026nbsp;6\\u003c/b\\u003e. Up to 56.1% of the population evaluated experienced daily pruritus beginning of the follow-up and the end of the follow-up period, only 17.7% of the entire population still reported pruritus. A reduction of this symptom by more than 50% is indicative of effective disease control with the prescribed therapies. Specifically, among patients receiving dupilumab therapy, there was an average reduction in disease severity scales of over 30% from the beginning to the end of follow-up.\\u003c/p\\u003e\"},{\"header\":\"Discussion\",\"content\":\"\\u003cp\\u003eAtopic dermatitis is a disease that has been increasing in recent decades. It usually presents in childhood, however the prevalence of the disease in adolescents and adults has been increasing (\\u003cspan citationid=\\\"CR8\\\" class=\\\"CitationRef\\\"\\u003e8\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR15\\\" class=\\\"CitationRef\\\"\\u003e15\\u003c/span\\u003e). Data on the prevalence of AD in these populations is scarce, with very few studies describing the age of onset, behavior, and frequency of the disease at these ages (\\u003cspan citationid=\\\"CR8\\\" class=\\\"CitationRef\\\"\\u003e8\\u003c/span\\u003e). Our study included children and adults with a diagnosis of atopic dermatitis; of the total population evaluated, only 32.2% were younger than 18 years of age. In 65.1% of the patients evaluated, the age of symptom onset was before 2 years of age. Comparing data from the literature and our data, we can highlight that the frequency of the disease in adults is significant, as well as the relevance of the age of onset in this population and the frequency of persistence of the disease that started in childhood (\\u003cspan citationid=\\\"CR16\\\" class=\\\"CitationRef\\\"\\u003e16\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eRecent studies suggest that there is considerable heterogeneity in the age of onset of AD, highlighting the fact that 1 in 4 adults with AD report that their disease began in adulthood (\\u003cspan citationid=\\\"CR17\\\" class=\\\"CitationRef\\\"\\u003e17\\u003c/span\\u003e). Our study had a predominance of adult patients, in which the most frequent location of the lesions were the flexural folds and extensor surfaces, in contrast to populations younger than 18 years, in which the most frequent location included both extensor surfaces and the face. In the literature we found that AD in adulthood is associated with higher rates of plantar dermatitis, lower predominance of lesions in flexural areas and lower rates of other characteristic signs (\\u003cspan citationid=\\\"CR17\\\" class=\\\"CitationRef\\\"\\u003e17\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR18\\\" class=\\\"CitationRef\\\"\\u003e18\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eThis makes diagnosis more difficult at this age, increasing the difficulty in distinguishing AD from other entities such as allergic contact dermatitis and cutaneous T-cell lymphoma (\\u003cspan citationid=\\\"CR18\\\" class=\\\"CitationRef\\\"\\u003e18\\u003c/span\\u003e). The development of the disease or its persistence associated with the severity of AD in adults jeopardizes productivity and the rate of labor insertion (\\u003cspan citationid=\\\"CR19\\\" class=\\\"CitationRef\\\"\\u003e19\\u003c/span\\u003e). The severity and complications of AD may be associated with the tendency to develop skin infections, which in our study was present in 14.7% of the population evaluated. These infections usually begin in a focal area of the skin but can spread rapidly and cover extensive areas of the body surface. It is important to be able to differentiate severe exacerbation from AD which may have more generalized cutaneous signs and symptoms such as erythema, swelling, oozing and tenderness, all of which can also be signs of skin infections (\\u003cspan citationid=\\\"CR16\\\" class=\\\"CitationRef\\\"\\u003e16\\u003c/span\\u003e). Given the impact of AD on patients' quality of life. We found that in the patients evaluated there was a significant decrease in the DLQI value at the end of follow-up. Considering that the good control of the disease is not only influenced by the adequate selection of therapies, but also by the multidisciplinary management of these patients and the capacity to respond to any complication. The evaluation of underlying psychiatric disorders helps to improve the quality of life of patients, achieving greater adherence to therapies and better response rates to the established treatments. There is emerging evidence suggesting that AD is associated with depression and anxiety (\\u003cspan citationid=\\\"CR20\\\" class=\\\"CitationRef\\\"\\u003e20\\u003c/span\\u003e). Some 30\\u0026ndash;60% of patients with dermatologic disease have some type of mental health problem (\\u003cspan citationid=\\\"CR18\\\" class=\\\"CitationRef\\\"\\u003e18\\u003c/span\\u003e). In a case-control study exploring routinely collected data from the UK Clinical Practice Research Datalink, a significantly increased risk of depression as well as anxiety incidence in patients with AD was demonstrated (\\u003cspan citationid=\\\"CR18\\\" class=\\\"CitationRef\\\"\\u003e18\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR21\\\" class=\\\"CitationRef\\\"\\u003e21\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eOur study reveals a prevalence of psychiatric disorders in up to 7.3% of the total population under evaluation, a figure notably lower compared to other studies where frequencies of up to 18.8% have been documented. The lower incidence of psychiatric disorders observed in our study may be attributed to several factors. Firstly, our patient follow-up program lacks the involvement of medical specialists in psychiatry. Additionally, when referrals to health insurance companies are made, the availability of specialists in this field is limited, resulting in lengthy waiting times for appointments. Furthermore, the absence of standardized employment of psychiatric evaluation scales during assessments hampers the detection of such pathologies (\\u003cspan citationid=\\\"CR22\\\" class=\\\"CitationRef\\\"\\u003e22\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eThis agrees with reports in the literature, which highlight that obesity is one of the comorbidities defined as a risk factor for AD and has also been associated with more severe disease. However, the specific mechanisms that explain the connection between obesity and AD are not yet fully recognized (\\u003cspan citationid=\\\"CR23\\\" class=\\\"CitationRef\\\"\\u003e23\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR24\\\" class=\\\"CitationRef\\\"\\u003e24\\u003c/span\\u003e). Obesity is known to be a metabolic disorder that often manifests early in life and is associated with reduced bacterial diversity in the gastrointestinal tract. Several lines of evidence suggest that obesity increases the severity of allergic diseases. Obese patients with immune diseases such as atopy and asthma have more severe disease compared to lean individuals (\\u003cspan citationid=\\\"CR24\\\" class=\\\"CitationRef\\\"\\u003e24\\u003c/span\\u003e). The identification of these risk factors and the intervention to correct them is of great importance for the adequate control of symptoms in patients with atopic dermatitis. The results of our study coincide with the literature, showing that topical therapy including emollients, topical steroids and calcineurin inhibitors are the most frequently used combinations of therapy with a percentage of 91% in the evaluated population. Systemic therapies are the first option in severe AD, the selection of these therapies is made based on the severity of the disease and according to previous therapies received. The use of biologic therapy is indicated in patients with severe clinical and quality of life impairment. Among the biologic products, dupilumab is authorized in other countries for children from 6 months of age and in Colombia from 6 years of age (\\u003cspan citationid=\\\"CR25\\\" class=\\\"CitationRef\\\"\\u003e25\\u003c/span\\u003e).\\u003c/p\\u003e \\u003cp\\u003eOral JAK inhibitors, such as baricitinib, abrocitinib and upadacitinib, have been approved in adolescents when other drugs, including biologics, have failed, or are contraindicated (\\u003cspan citationid=\\\"CR13\\\" class=\\\"CitationRef\\\"\\u003e13\\u003c/span\\u003e). Data on the use of these biologic therapies or others such as crisaborole were not included in the study, as they were approved after the recruitment dates of the study patients. It is crucial to understand the characteristics of a disease in children and adults for a complete and personalized management. It is important to know data such as age of onset, symptoms, location of common lesions according to age, comorbidities, and responses to treatments. This information is essential for choosing appropriate therapies, ensuring effective follow-up, and improving quality of life. The participants of this study constitute a representative cohort of patients with atopic dermatitis followed in a health institution specialized in the management and control of immune-mediated diseases. The availability and use of biologic drugs has expanded treatment options for patients with moderate to severe AD, particularly for those who have not achieved satisfactory results with conventional therapies or who have contraindications to systemic immunosuppressive agents. These drugs provide a more targeted and personalized approach, reducing symptoms, improving quality of life and preventing long-term complications associated with uncontrolled disease as we see in the results.\\u003c/p\\u003e \\u003cdiv id=\\\"Sec8\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003eLimitations\\u003c/h2\\u003e \\u003cp\\u003eAlthough important and complete information is shown for a significant number of patients with AD, we consider that the follow-up time was short, which limits the evaluation of the effect of the therapy or the use of other therapies. Most of the patients belong to the contributory health care system; we do not know information on the characteristics and behavior of the population in other socioeconomic spheres, where probably the lack of access to this type of programs may show a greater severity of symptoms and a limitation in the use of therapies for the control of the disease. Since the clinical histories are not pre-tabulated, there were variables with few data, other data do not appear since the study was retrospective. The prevalence of psychiatric disorders related to the disease was low; we suggest the implementation of screening scales for these pathologies to assess their impact on the severity of the disease. It is important given the frequency of these reported in the literature that they be included in the follow up evaluation by psychiatry.\\u003c/p\\u003e \\u003c/div\\u003e\"},{\"header\":\"Abbreviations\",\"content\":\"\\u003cdiv class=\\\"DefinitionList\\\"\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eAD\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eAtopic dermatitis\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eCLIPSO\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eClinical Program for Immune-Mediated Skin Diseases\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eUVB\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eUltraviolet B\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eUVA1\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eUltraviolet A1\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eEASI\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eEczema Area and Severity Index\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003ePOEM\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003ePatient Oriented Eczema Measure\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003cdiv class=\\\"DefinitionListEntry\\\"\\u003e \\u003cdiv class=\\\"Term\\\"\\u003eDLQI\\u003c/div\\u003e \\u003cdiv class=\\\"Description\\\"\\u003e \\u003cp\\u003eDermatology Life Quality Index\\u003c/p\\u003e \\u003c/div\\u003e \\u003c/div\\u003e \\u003c/div\\u003e\"},{\"header\":\"Declarations\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eEthical approval:\\u003c/strong\\u003e This research article was reviewed and approved by the Research and Innovation Committee of the Faculty of Medicine, Universidad CES, No. Act No. 289 of August 17, 2022, and was conducted following the Declaration of Helsinki and recommendations of the Council for International Organizations of Medical Sciences.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAcknowledgements:\\u003c/strong\\u003e Don\\u0026rsquo;t apply\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eConsent to publish statement:\\u003c/strong\\u003e Patient consent was not required because this study was performed retrospectively.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eConflict of Interest Statement:\\u0026nbsp;\\u003c/strong\\u003eThe authors declare that they have no competing interests to disclose.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eFunding:\\u0026nbsp;\\u003c/strong\\u003eThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAuthor Contributions:\\u0026nbsp;\\u003c/strong\\u003eAll authors contributed equally to this work.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eData Availability Statement:\\u0026nbsp;\\u003c/strong\\u003eThe data sets used during the present study are available from the corresponding author upon reasonable request.\\u003c/p\\u003e\"},{\"header\":\"References\",\"content\":\"\\u003col\\u003e\\u003cli\\u003e\\u003cspan\\u003eSonja St\\u0026auml;nder 1. Atopic Dermatitis. N Engl J Med. 2021;25(384(12)):1136\\u0026ndash;43.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eThomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment. ISRN Allergy. 2014;2014:1\\u0026ndash;7.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eNutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(Suppl. 1):8\\u0026ndash;16.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eSacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595\\u0026ndash;605.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eLondo\\u0026ntilde;o AM, Castro-Ayarza JR, Kronfly A, Buitrago DC, Samac\\u0026aacute; DF. Epidemiolog\\u0026iacute;a y uso de recursos de salud en dermatitis at\\u0026oacute;pica en Colombia: an\\u0026aacute;lisis retrospectivo de datos del Registro Nacional de Salud de 2015 a 2020. Biom\\u0026eacute;dica. 2023;43(1):107\\u0026ndash;20.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eCuervo MM, Sanclemente G, Barrera LM. Caracterizaci\\u0026oacute;n cl\\u0026iacute;nica, sociodemogr\\u0026aacute;fica y determinaci\\u0026oacute;n del impacto en la calidad de vida de pacientes con dermatitis at\\u0026oacute;pica de la ciudad de Medell\\u0026iacute;n y su \\u0026aacute;rea metropolitana. Biom\\u0026eacute;dica. 2021;41(4):676\\u0026ndash;91.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eFacheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448\\u0026ndash;74.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eRam\\u0026iacute;rez-Mar\\u0026iacute;n HA, Silverberg JI. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022;39(3):345\\u0026ndash;53.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eLi H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324\\u0026ndash;38.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eRadi G, Campanti A, Diotallevi F, Martina E, Marani A, Offidani A. A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside. Biomedicines. 2022;10(11):2700.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eGooderham M, Boguniewicz M, Sher L, Weisman J, Bansal A, Staudinger HW, et al. Dupilumab in children aged\\u0026thinsp;\\u0026ge;\\u0026thinsp;6 to \\u0026lt;\\u0026thinsp;12 years significantly improves severe atopic dermatitis: Results from phase 3 trial (LIBERTY AD PEDS). Australasian Journal of Dermatology. 2021;62(SUPPL 1).\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eCaffarelli C, Giannetti A, Giann\\u0026igrave; G, Ricci G. Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. Front Med (Lausanne). 2023;10.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eWan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to‐severe atopic dermatitis: A network meta‐analysis. Dermatol Ther. 2022;35(9).\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eEichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\\u0026ndash;51.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eLee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526\\u0026ndash;1532.e7.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eWang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Annals of Allergy, Asthma \\u0026amp; Immunology. 2021;126(1):3\\u0026ndash;12.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eHanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index\\u0026mdash;A Practical Guide. Dermatitis. 2022;33(3):187\\u0026ndash;92.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eBarbieri JS, Chiesa Fuxench ZC, Shin DB, Takeshita J. Frequency and influence of \\u0026ldquo;not relevant\\u0026rdquo; responses on the Dermatology Life Quality Index among adults with atopic dermatitis. Quality of Life Research. 2021;30(6):1705\\u0026ndash;13.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003ePatruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242\\u0026ndash;9.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eBaurecht H, Welker C, Baumeister S -E., Weidnger S, Meisinger C, Leitzmann MF, et al. Relationship between atopic dermatitis, depression and anxiety: a two‐sample Mendelian randomization study. British Journal of Dermatology. 2021;185(4):781\\u0026ndash;6.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eTohid H, Shenefelt PD, Burney WA, Aqeel N. Psychodermatology: An Association of Primary Psychiatric Disorders With Skin. Rev Colomb Psiquiatr. 2019;48(1):50\\u0026ndash;7.\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eR\\u0026oslash;nnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol [Internet]. 2018;79(3):448\\u0026ndash;456.e30. Available from: \\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003ehttps://linkinghub.elsevier.com/retrieve/pii/S0190962218304675\\u003c/span\\u003e\\u003cspan address=\\\"https://linkinghub.elsevier.com/retrieve/pii/S0190962218304675\\\" targettype=\\\"URL\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eZhang S, Zhang B, Liu Y, Li L. Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis. Lipids Health Dis [Internet]. 2024;23(1):26. Available from: \\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003ehttps://lipidworld.biomedcentral.com/articles/\\u003c/span\\u003e\\u003cspan address=\\\"https://lipidworld.biomedcentral.com/articles/\\\" targettype=\\\"URL\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003e10.1186/s12944-024-02009-z\\u003c/span\\u003e\\u003cspan address=\\\"10.1186/s12944-024-02009-z\\\" targettype=\\\"DOI\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eMcAleer JP. Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists. Frontiers in Allergy [Internet]. 2023;4. Available from: \\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003ehttps://www.frontiersin.org/articles/\\u003c/span\\u003e\\u003cspan address=\\\"https://www.frontiersin.org/articles/\\\" targettype=\\\"URL\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003e10.3389/falgy.2023.1167800/full\\u003c/span\\u003e\\u003cspan address=\\\"10.3389/falgy.2023.1167800/full\\\" targettype=\\\"DOI\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/li\\u003e \\u003cli\\u003e\\u003cspan\\u003eWollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults. Dtsch Arztebl Int. 2023; doi:\\u003cspan class=\\\"ExternalRef\\\"\\u003e\\u003cspan class=\\\"RefSource\\\"\\u003e10.3238/arztebl.m2023.001\\u003c/span\\u003e\\u003cspan address=\\\"10.3238/arztebl.m2023.001\\\" targettype=\\\"DOI\\\" class=\\\"RefTarget\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e.\\u003c/span\\u003e\\u003c/li\\u003e\\u003c/ol\\u003e\"},{\"header\":\"Tables\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eTable N.1\\u003c/strong\\u003e\\u003cstrong\\u003e\\u0026nbsp;Demographic data of patients with Atopic Dermatitis and subpopulation of patients with AD receiving biologic therapy.\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"555\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"100%\\\" colspan=\\\"3\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTable N\\u0026deg;1. Demographic data of patients with Atopic Dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePatients with Atopic Dermatitis\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTotal (n= 301)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePatients with AD who received biological therapy\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDemographic Characteristics\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003en (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTotal (n= 134)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eMean age (IQR)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e26,76 (19,95)\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e27.99(13,67)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eGender, n (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFemale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e189(62,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e86(64,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e112(37,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e48(35,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eMarital status\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eSingle\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e236(78,4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e101(75,4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMarried\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e35(11,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e15(11,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eUnmarried\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e23(7,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e15(11,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eDivorced\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(1,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(2,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003ewidowed\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e2(0,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e0(0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAffiliation\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eContributory\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e293(97,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e129(96,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eSpecial\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e8(2,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(3,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eGeographic region n (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAntioquia\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e288(95,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e128(95,5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eBogot\\u0026aacute; DC\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(0,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(0,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCauca\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(0,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e0(0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eValle del Cauca\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11(3,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(3,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eZone\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eUrban\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e298(99)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e131(97,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eRural\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(2,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSchooling\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003ePrimary\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e55(18,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14(10,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eSecondary\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e118(39,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e51(39,5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eProfessional\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e64(21,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e42(32,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003ePostgraduate\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(1,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(3,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eNo studies\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e16(5,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e17(13,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eTechnical/technological\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e37(12,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e0(0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSocioeconomic stratum\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eLow\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e62(20,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e21(15,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMedium\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e213(70,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e96(71,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"47.84172661870504%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eHigh\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"22.12230215827338%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e26(8,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"30.035971223021583%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e17(12,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable N. 2 Clinical characteristics of patients with Atopic Dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"589\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTableN\\u0026deg;2 Clinical characteristics of patients with Atopic Dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eEarly onset in childhood (\\u0026lt;2 years)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e196(65,1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eChronic Recurrent Symptoms\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e289(96,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDistribution of skin lesions Total=294\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFacial\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e7(2,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFlexural folds\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e68(22,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eExtensor surfaces\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e31(10,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFacial and flexural folds\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e32(10,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFacial and extensor surfaces\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e17(5,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFlexural folds and extensor surfaces\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e69(22,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFacial, flexural folds, extensor surfaces\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e70(23,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDistribution of lesions by age range\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e2-12 years\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e13-17 years\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026gt; 18 years\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAge ranges n (%) Total =301\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e46(15,28)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e51(16,94)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e204(67,77)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFacial\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e0(0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(1,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6(2,94)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFlexural folds\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(6,97)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10(19,60)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e55(26,96)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eExtensor surfaces\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6(13,04)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(1,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e24(11,76)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFacial and flexural folds\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e0(0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(5,88)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e29(14,21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFacial and extensor surfaces\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(10,86)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e21(41,1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e12(5,88)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFlexural folds and extensor surfaces\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6(13,04)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14(27,45)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e72(35,29)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAtopic stigmata\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eXerosis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e253(83,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFacial pallor\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e76(25,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDermographism\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(1,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eIchthyosis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e2(7.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePalmar hyperlinearity\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e19(6,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePityriasis Alba\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e20(6,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePilar keratosis\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e20(6,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePerifollicular accentuation\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e23(7,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePeriocular darkening\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e48(15,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eLichenification\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e117(38,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTendency to cutaneous infections\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e44(14,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eFamily History (n=301)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAsthma\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e26(8,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eRhinitis\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e39(13,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAtopic dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e44(14,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAsthma and rhinitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e61(20,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAsthma and atopic dermatitis\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e15(5,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.49152542372882%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eAsthma, rhinitis, dermatitis\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.796610169491526%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e39(13,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.084745762711865%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"17.627118644067796%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003cbr\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"543\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"100%\\\" colspan=\\\"2\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTable N.3: Associated Comorbidities in Patients with Atopic Dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAtopic Comorbidities (n=215)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAsthma\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e32(14.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eRhinitis\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e85(39.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eFood allergy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e4(1.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAsthma/rhinitis\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e76(35.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAsthma/food allergy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(2.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eRhinitis/food allergy\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e4(1.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAsthma/rhinitis/dermatitis\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e9(4.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePsychiatric Comorbidities (n=22)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAnxiety\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e4(18.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eDepression\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(22.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eSchizophrenia\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(4.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eBipolar affective disorder\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(4.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAttention deficit\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e4(18.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAnxiety/depression\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(13.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAnxiety/depression/suicidal behavior\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(4.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAnxiety/depression/attention deficit\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(13.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eOther Comorbidities (n=32)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMicrocytic anemia\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eDyslipidemia\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(15.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eType 2 Diabetes Mellitus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eObesity\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e9(28.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eArterial hypertension\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6(18.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eType 2 DM/dyslipidemia\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(9.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eType 2 DM/arterial hypertension/obesity\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e3(9.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eArterial hypertension/dyslipidemia\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eArterial hypertension/coronary artery disease\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eArterial hypertension/chronic kidney disease\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"73.11233885819522%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eArterial hypertension/type 2 DM/dyslipidemia/coronary artery disease\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"26.887661141804788%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(3.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable N.4 Combination of therapies used in the management of patients with atopic dermatitis.\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"584\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"100%\\\" colspan=\\\"2\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTable N.4 Combination of therapies used in the management of patients with atopic dermatitis\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTreatment (n=294)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003en (%)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTopical therapy\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e274(91.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eEmollients\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10(3.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCorticosteroids\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e26(9.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eTacrolimus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10(3.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eEmollients/Corticosteroids\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e42(15.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eEmollients/Tacrolimus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5(1,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCorticosteroids/Tacrolimus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e35(12.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eEmollients/Corticosteroids/Tacrolimus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e145(52.9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNon-biologic systemic therapy\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e197(65.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eAzathioprine\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e1(0,3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMethotrexate\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e45(22,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCyclosporine\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e30(10,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCorticosteroids\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e12(6,1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eMycophenolate mofetil\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e2(1,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eCombinations\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e40(20,2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePhototherapy\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e74(25,17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eSystematic Biological Therapy\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDupilumab\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e134(44.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"78.08219178082192%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003eBaricitinid\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.91780821917808%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e2(0,66)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable No. 5: Clinical measurements at the beginning and end of follow-up in patients with AD, variations according to treatment\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"697\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTreatment (n=294)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePOEM score Initial\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePOEM score final\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eEASI score initial\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eEASI score final\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDLQI score initial\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eDLQI score final\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eTopical therapy\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e15,96(8,65)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e8,73(7,23)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,44(12,33)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,39(9,33)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10,5(8,46)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,27(6,7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNon-biological systemic therapy \\u0026nbsp;\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14,17(8,25)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10,16(7,39)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,57(10,73)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,92(7,08)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,26(8,09)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e7,87(7,27)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eMethotrexate\\u003c/em\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14,57(8,54)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10,86(6,68)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e13,41(9,72)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e7,61(7,1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,30(7,60)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,94(6,86)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eCyclosporine\\u003c/em\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14,92(8,55)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e8,96(7,31)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,22(11,79)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,31(9,15)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,37(8,54)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,14(6,4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003ePhototherapy\\u0026nbsp;\\u003c/em\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e15,11(8,64)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e8,98 (7,31)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,23(12,25)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,21(9,49)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e10,61(8,52)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,26(6,68)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eBiological therapy\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e14,86(8,86)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e7,97(7,38)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e12,30(12,61)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6,35(8,82)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e11,32(9,06)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e5,84(6,66)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"21.695402298850574%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u003cem\\u003eData are mean (+/-SD)\\u003c/em\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.511494252873563%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.218390804597702%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"12.068965517241379%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable No. 6: Evaluation of pruritus at the beginning and end of follow-up\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"439\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003ePruritus\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e(Follow-up)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eBeginning (n=285)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eEnd(n=259)\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003en (%)\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003en (%)\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eNo day\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e28(9,8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e84(32,43)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e1-2 Days\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e36(12,6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e84(32,43)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e3-4 Days\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e31(10,9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e38(14,67)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e5-6 Days\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e21(7,0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e6(2,31)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"34.39635535307517%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003eEvery day\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"34.16856492027335%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e169(56,1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"31.43507972665148%\\\" valign=\\\"top\\\"\\u003e\\n \\u003cp\\u003e46(17,76)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\"}],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":true,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":true,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":false,\"isAuthorSuppliedPdf\":false,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":false,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true},\"keywords\":\"dermatitis, atopic, prevalence, treatment, pruritus, biological therapy\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-4467272/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-4467272/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"\\u003ch2\\u003eIntroduction:\\u003c/h2\\u003e \\u003cp\\u003eAtopic dermatitis (AD) is a chronic and recurrent inflammatory disease that begins in childhood and can persist into adulthood, with significant impact on quality of life. However, there is a lack of data on its characteristics and treatment in Colombia and Latin America.\\u003c/p\\u003e\\u003ch2\\u003eObjective:\\u003c/h2\\u003e \\u003cp\\u003eTo describe the clinical and sociodemographic characteristics, quality of life, and treatment responses in patients with AD at a referral center in the city of Medell\\u0026iacute;n, Colombia.\\u003c/p\\u003e\\u003ch2\\u003eMaterials and Methods:\\u003c/h2\\u003e \\u003cp\\u003eA retrospective descriptive study was conducted analyzing demographic, clinical, and treatment response data, including biologic therapy, in patients with AD treated at the Comprehensive Clinical Program for Immune-Mediated Skin Diseases (CLIPSO) during the period 2018\\u0026ndash;2022 in Medell\\u0026iacute;n, Colombia.\\u003c/p\\u003e\\u003ch2\\u003eResults:\\u003c/h2\\u003e \\u003cp\\u003eA total of 301 patients, including children and adults, with a mean age of 26.76 years were studied. 32.2% were under 18 years old. The average follow-up was 33.23 +/- 22.11 months. Psychiatric disorders were detected in 7.3% of patients and cardiovascular comorbidities in 10.6%. At baseline, moderate to severe disease severity was observed. A 50% reduction in pruritus was associated with adequate disease control by therapy. Additionally, patients treated with dupilumab experienced a 30% decrease in clinical evaluation scores during follow-up.\\u003c/p\\u003e\\u003ch2\\u003eConclusions:\\u003c/h2\\u003e \\u003cp\\u003eUnderstanding the characteristics of a disease in both children and adults is crucial for comprehensive and personalized management. It is important to know data such as age of onset, symptoms, common lesion locations according to age, comorbidities, and treatment responses. This information is fundamental for selecting appropriate therapies, ensuring effective follow-up, and improving quality of life.\\u003c/p\\u003e\",\"manuscriptTitle\":\"Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Center between 2018 and 2022\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2024-06-18 17:21:08\",\"doi\":\"10.21203/rs.3.rs-4467272/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"c7a36959-3f3f-4ddb-9084-6b6d79343ba7\",\"owner\":[],\"postedDate\":\"June 18th, 2024\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"posted\",\"subjectAreas\":[],\"tags\":[],\"updatedAt\":\"2024-07-15T11:29:15+00:00\",\"versionOfRecord\":[],\"versionCreatedAt\":\"2024-06-18 17:21:08\",\"video\":\"\",\"vorDoi\":\"\",\"vorDoiUrl\":\"\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-4467272\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-4467272\",\"identity\":\"rs-4467272\",\"version\":[\"v1\"]},\"buildId\":\"qtupq5eGEP_6zYnWcrvyt\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}